CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

Denmark and USA-based contract manufacturers CMC Biologics and US biopharma start-up OncoSynergy have entered into an agreement for process development and Good Manufacturing Practices (GMP) production of OS2966 – a novel potential treatment for Ebola.

The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the US Food and Drug Administration earlier this year in the treatment of glioblastoma. Previous studies have suggested CD29 is required for Ebola virus infection; blocking CD29 could halt Ebola's spread in the body.

CD29 efficacy demonstrated in laboratory models